Eyevance Pharmaceuticals LLC.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eyevance Pharmaceuticals LLC.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Eyevance Pharmaceuticals, LLC